Volume 42, November 2007 O ver the past several years, a focal point for the media has been drug safety in regards to the medical community and the Food and Drug Administration (FDA). Numerous editorials, stories, and papers have been published on the subject. We have also seen Congress and the public get more interested in the subject, as illustrated by the recent debate over continuing the FDA's user fees and increasing the responsibility of the FDA when it comes to drug safety issues.
A recently published study in the Archives of Internal Medicine 1 looked at the serious adverse drug events (ADEs) reported to the FDA between 1998 and 2005. This group of researchers found the number of ADEs reported increased 2.6-fold and fatal ADEs increased by 2.7-fold during this time. A number of these events were reported by the manufacturer and included new, serious events not contained within the product labeling. Not surprising was that a disproportionate share of the ADEs involved elderly patientseven after accounting for their increased use of medications. None of us are surprised that drug therapy can result in harm, even when used appropriately, but it is our responsibility as health care providers to assure patient safety is not unnecessarily compromised. This requires us to keep informed with new reports and labeling changes related to drug safety.
For years, the FDA has published information on their Med-Watch Web site (http://www.fda. g o v / m e d w a t c h / i n d e x . h t m l ) regarding safety changes in product labeling. The busy practitioner can also get a copy of these updates e-mailed to them by subscribing to the MedWatch LIST-SERVE (https://list.nih.gov/cgibin/wa?SUBED1=medwatch&A=1).
The latest way to keep apprised of this subject is the new FDA newsletter, Drug Safety Newsletter, produced by the Center for Drug Evaluation and Research Safety Policy and Communication staff. The mission of this newsletter is to provide postmarketing information to health care professionals regarding drug safety, raise the awareness of reported ADEs, and stimulate reporting of additional ADEs.
The inaugural issue contained stories on rituximab and progressive multifocal leukoencephalopathy, modafinil and serious skin reactions, temozolomide, aplastic anemia, as well as a new safety finding regarding deferasirox. It also contained a reminder on how to report an adverse reaction and highlights of drug safety communications issued by the FDA. The newsletter can be obtained electronically at http://www.fda.gov/ cder/dsn/. You can also subscribe to receive future copies of this newsletter at the same URL.
While it is very easy to criticize the FDA when it comes to various actions, or lack thereof, related to drug safety, they should be congratulated for putting together such a valuable resource for the busy practitioner. The availability of these types of resources in addition to the activities of the Institute for Safe Medication Practices can help all of us provide our patients with safer care. However, the only way we can assure that our patients get the safest care possible is to be informed and to continue to report adverse drug reactions on all medications-not just those that are newly approved.
Hospital Pharmacy 979
CONSULTANT PHARMACIST DRUG THERAPY RECOMMENDATIONS IN A GERIATRIC NURSING FACILITY
Dear Editor:
The American Society of Consultant Pharmacists (ASCP), which represents 7,000 consultant and senior care pharmacists, cautions against extrapolating the results of the study published in the August 2007 edition of Hospital Pharmacy entitled "Consultant Pharmacist Drug Therapy Recommendations in a Geriatric Nursing Facility" (Hosp Pharm. 2007; 42:729-736).
While the results of this study showed physicians accepted only 15% of consultant pharmacist recommendations, the article acknowledges the study's limitations by stating, "The limitations of this study are that it was in only one facility and represented a very small segment of the population served by consultant pharmacists."
The small size of the study group is not an accurate representation of typical consultant pharmacy practice nationwide. ASCP's membership survey, which occurs approximately every 2 years, consistently reveals a higher acceptance rate for consultant pharmacist recommendations. Our last survey, which was conducted in 2005 and answered by nearly half of our active members, revealed that, in a typical month, there was a 66% average acceptance rate of consultant pharmacist recommendations; the majority of ASCP members said that they experienced a nearly 75% acceptance by physicians of their recommendations. As explained in the article, the very low acceptance rate in the most recent year is likely a result of a change in physician staffing and medical director at the facility.
In addition, previous studies conducted by the same researcher in the same nursing facility 1 to 3 years prior, revealed significantly higher acceptance rates than this study's average acceptance rate. In fact, the author's initial 1-year study 1 documented a nearly 93% acceptance of the consultant pharmacist's recommendations, and the subsequent 2-year study 2 revealed an 89.3% acceptance rate of recommendations. These previous study results are outlined in the recent article.
Another point to consider is that this study was conducted a number of years ago before recent changes in the Centers for Medicare & Medicaid Services (CMS) State Operations Manual, which now requires additional documentation to accompany a physician's rejection of a consultant pharmacist's recommendation. Prior to implementation of the revised interpretive guidelines accompanying F-Tag 428 (Medication Regimen Review), 3 physicians had to act upon a consultant pharmacist's report or recommendations by simply indicating acceptance or rejection, but they did not have to supply a rationale for their decision. The new interpretive guidelines now require documentation of the physician's rationale for rejection of a consultant pharmacist's recommendation. This enhanced documentation requirement is likely to increase the physicians' acceptance rate of pharmacists' recommendations since physicians can-not easily reject the recommendations without careful consideration and documentation.
The efficiency and quality of care provided in all health care settings are dependent on good communication and the building of relationships among clinicians. The same is true for consultant pharmacists practicing in the nursing facility setting. Therefore, consultant pharmacists who have good relationships with the prescribers and staff in their facilities, and who have gained the trust and respect of their colleagues, typically experience a greater acceptance rate of their medication-related recommendations.
The Hospital Pharmacy article mentions the misperception by physicians of pharmacists' consultations: "The CP [Consultant Pharmacist] recommendations were in fact perceived by the newer physicians as the unwelcome intrusion of unsolicited consultations that crossed and exceeded the professional boundaries of care responsibilities that exist between medicine, nursing, and pharmacy." A strong working relationship with prescribers-especially with those new to nursing facilities-can help limit misinterpretation of or negative connotations associated with the pharmacists' medication regimen reviews. After all, this requirement is mandated by CMS to ensure that the medications received by patients are appropriate. In short, it is a check and balance in the system.
The high recommendation acceptance rate noted by ASCP members in the survey mentioned above may be attributed to the strong professional relationships
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